How should I manage a patient with stage 1 hypertension who has blood pressure readings of 144/92 and 144/88?

Management of Stage 1 Hypertension (BP 144/92 and 144/88)

Start lifestyle interventions immediately, and if this patient has high-risk features (CVD, CKD, diabetes, organ damage, or age 50-80 years), initiate pharmacological treatment now; otherwise, start drug therapy only if BP remains elevated after 3-6 months of lifestyle modification. 1

Risk Stratification Determines Treatment Timing

The 2020 ISH guidelines provide clear direction for these blood pressure readings (144/92 and 144/88), which fall into Grade 1 hypertension (140-159/90-99 mmHg) 1:

Immediate Drug Treatment Required For:

• High-risk patients: Those with established CVD, CKD, diabetes, hypertension-mediated organ damage, or aged 50-80 years 1
• These patients should start medication immediately alongside lifestyle interventions

Delayed Drug Treatment (3-6 months) For:

• Low-to-moderate risk patients: All others without the above conditions
• Start with intensive lifestyle interventions
• Add pharmacological therapy only if BP remains ≥140/90 mmHg after 3-6 months 1

This risk-stratified approach is supported by the 2024 ESC guidelines, which emphasize that treatment decisions for stage 1 hypertension should be based on 10-year CVD risk ≥10% or presence of high-risk conditions 2. The 2025 ACC/AHA guidelines similarly recommend that stage 1 hypertension warrants immediate combination therapy in high-risk patients 3.

Confirm the Diagnosis First

Before proceeding with treatment decisions, confirm hypertension with out-of-office measurements 1:

• Home BP ≥135/85 mmHg, or
• 24-hour ambulatory BP ≥130/80 mmHg

This step is critical because office readings can overestimate true BP, leading to unnecessary treatment. Use a validated automated upper-arm cuff device with appropriate cuff size 1.

Lifestyle Interventions (All Patients)

Implement these evidence-based modifications immediately 1, 4:

• DASH diet (Dietary Approaches to Stop Hypertension)
• Sodium restriction (<2g/day)
• Potassium enrichment (unless contraindicated)
• Regular aerobic exercise (150 minutes/week moderate intensity)
• Weight loss if overweight (target BMI <25 kg/m²)
• Alcohol moderation (≤2 drinks/day for men, ≤1 for women)

Pharmacological Treatment Algorithm

For Non-Black Patients 1:

1. Start: Low-dose ACEi or ARB
2. If inadequate: Add DHP-CCB
3. If still inadequate: Increase to full dose
4. Next step: Add thiazide-like diuretic
5. Resistant cases: Add spironolactone (or alternatives: amiloride, doxazosin, eplerenone, clonidine, or beta-blocker)

For Black Patients 1:

1. Start: Low-dose ARB + DHP-CCB, or DHP-CCB + thiazide-like diuretic
2. If inadequate: Increase to full dose
3. Next step: Add diuretic or ACEi/ARB
4. Resistant cases: Add spironolactone (or alternatives as above)

Consider monotherapy only in low-risk Grade 1 hypertension, patients aged >80 years, or frail patients 1.

Treatment Targets and Monitoring

Target BP: <130/80 mmHg 1

• Minimum goal: Reduce BP by at least 20/10 mmHg
• Achieve target within 3 months 1
• For elderly patients, individualize based on frailty status

The 2025 ACC/AHA guidelines support this lower target, though the 2020 ISH guidelines acknowledge that 140/90 mmHg may be acceptable in some contexts 3, 1. However, observational data from Korean populations demonstrate that achieving BP <140/90 mmHg in stage 1 hypertension significantly reduces mortality, stroke, and end-stage renal disease, with optimal BP ranges of 120-130/70-80 mmHg 5.

Critical Pitfalls to Avoid

1. Therapeutic inertia: Don't delay treatment in high-risk patients—the evidence shows increased cardiovascular events and mortality with untreated stage 1 hypertension in this population 6

2. White coat hypertension: Always confirm with home or ambulatory monitoring before committing to lifelong therapy 7

3. Inadequate lifestyle trial: In low-risk patients, give a full 3-6 months of intensive lifestyle modification before adding medications 1

4. Monotherapy in high-risk patients: These patients typically need combination therapy from the start 3

5. Ignoring nocturnal BP: Consider 24-hour ABPM, as nocturnal stage 1 hypertension (110-120/65-70 mmHg) independently predicts kidney disease progression 8

Special Considerations

Age ≥85 years, frailty, or orthostatic hypotension: Exercise caution with aggressive BP lowering; consider deferring treatment until BP >140/90 mmHg and use lower targets 2. The risk-benefit ratio shifts in these populations due to increased adverse effects and competing mortality risks.

Single-pill combinations (SPCs): Strongly preferred over multiple separate pills when combination therapy is needed, as they improve adherence and reduce cardiovascular events 3.